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We read with enthusiasm the recent paper by Nakase et al.1
about the serum b-D-glucan level associated with Trichosporon
fungemia in patients with hematological disorders. They demon-
strated paradoxical results showing that early death from this
infection was more frequently seen in b-D-glucan negative
patients (n = 12) than in positive patients (n = 16), and that the
overall survival was signiﬁcantly worse in the negative patients
than in the positive patients.1 Although b-D-glucan is detected in
the serum of patients with invasive fungal infections, such as
Candida and Aspergillus fungemia, there have been only a few
studies in patients with Trichosporon fungemia.2,3
We retrospectively assessed the clinical signiﬁcance of b-D-
glucan in cases of Trichosporon fungemia. A questionnaire
concerning patients with this disease treated between 2000 and
2008 was sent to 725 hospitals in Japan in 2009; the clinical data
from a total 84 patients with Trichosporon fungemia were
collected from 43 hospitals. Among the 78 patients (60 malesFigure 1. Kaplan–Meier survival probability based on the serum b-D-glucan levels
(above or below 60 pg/ml). The Trichosporon fungemia patients with low b-D-
glucan levels (n = 40) tended to have better survival than those with high b-D-
glucan levels (n = 38), although there was no signiﬁcant difference between the two
groups (p = 0.125).
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evaluated for their serum b-D-glucan levels, 70 had underlying
hematological malignancies or other hematological disorders
associated with a poor prognosis. When patients were segregated
into two groups according to their median b-D-glucan level
(60 pg/ml), there were no signiﬁcant differences in the baseline
characteristics and clinical ﬁndings between the two groups other
than the 90-day mortality (median 30 (interquartile range 75) days
in the low b-D-glucan group vs. 35 (interquartile range 92) days in
the high b-D-glucan group; p = 0.04). However, a multivariable
analysis showed no signiﬁcant difference in the b-D-glucan levels
for predicting 90-day mortality (adjusted hazard ratio 1.463, 95%
conﬁdence interval 0.892–2.399, p = 0.132) in a Cox proportional
hazards model. In addition, the b-D-glucan levels did not affect the
overall survival in a log-rank test (Figure 1; p = 0.125).
The b-D-glucan molecule is a polysaccharide component
speciﬁc to the fungal cell wall. In other words, the b-D-glucan in
the serum is derived from the fungus itself and is not produced by
the host. Thus, the serum concentration in patients with fungemia
usually corresponds to the fungal burden. Since b-D-glucan is
reported to provoke host defense by the innate immune system,4 it
is of interest whether the elevated serum levels of b-D-glucan in
patients with Trichosporon fungemia reﬂect disease progression,
or activation of the host protective system against the fungus. It is
hoped that a large worldwide survey of patients with Trichosporon
fungemia can be accomplished in the future.
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